Clinical Trials with Alteplase (RT-pa) in Acute Myocardial Infarction

  • David P. de Bono
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 281)

Abstract

Alteplase (recombinant human tissue plasminogen activator, rt-PA) first became available for clinical trials in acute myocardial infarction in 1984 (1). At this time there was already considerable experience with thrombolysis using intracoronary streptokinase (2), and a consensus that the benefits of coronary thrombolysis operated through the early restoration of coronary patency. The potential benefits of rt-PA compared with streptokinase as seen in 1984 are listed in table 1 —the principal hope being that a “thrombus specific” agent such as rt-PA would provide more effective and rapid thrombolysis with a minimum of bleeding complications. The endpoint in the earliest trials (TIMI 1 and ECSG 1) was angiographic coronary patency — the “hardest” endpoint realistically attainable with the limited amounts of rt-PA then available. The results of these studies were favourable to rt-PA in comparison both with placebo (ECSG-1) and streptokinase (ECSG-2 and TIMI-1) but it was clear that larger studies would be needed both to provide adequate safety data for registration, and to provide more clearcut evidence concerning “outcome” measurements such as mortality and left ventricular function. Moreover the TIMI-1 study had raised a worry concerning the apparent high rate of reocclusion following rt-PA thrombolysis (3,4). The question of reocclusion was specifically addressed in ECSG-3, with reassuring results. Nevertheless, concern about reocclusion undoubtedly influenced subsequent trials both in terms of the use of a prolonged rt-PA infusion and a feeling that results might be further improved by combining thrombolysis with early angioplasty.

Keywords

Placebo Europe Aspirin Heparin Half Life 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    F. van de Werf, P. A. Ludbrook, S. R. Bergmann et al. Coronary thrombolysis with tissue type plasminogen activator in patients with evolving myocardial infarction. N. Engl. J. Med., 310:609–13 (1984).PubMedCrossRefGoogle Scholar
  2. 2.
    R. Schroeder, G. Biamino, E. R. Leitner et al. Intravenous short term infusion of streptokinase in myocardial infarction. Circulation, 67:536–48 (1983).CrossRefGoogle Scholar
  3. 3.
    The TIMI study group. The thrombolysis in myocardial infarction (TIMI) trial. Phase 1 findings. N. Engl. J. Med., 312:932–36 (1985).Google Scholar
  4. 4.
    D. O. Wiiliams, J. Borer, E. Braunwald et al. Intravenous recombinant tissue plasminogen activator in patients with myocardial infarction: a report from the NHLBI thrombolysis in myocardial infarction trial. Circulation, 73 (2):338–46 (1986).CrossRefGoogle Scholar
  5. 5.
    Gruppo Italiano per lo Studi deela Streptochinasi nell’ Infarto miocardico (GISSI). Effectiveness of intravenous thromboytic therapy in acute myocardial infarction. Lancet, i:397–401 (1986).Google Scholar
  6. 6.
    M. Verstraete, W. Bleifeld, R. W. Brower et al. Double blind randomized trial of intravenous recombinant tissue type plasminogen activator versus placebo in acute myocardial infarction. Lancet, ii:965–969 (1985).CrossRefGoogle Scholar
  7. 7.
    M. Verstraete, R. Bernard, M. Bory et al. Randomized trial of intravenous recombinant tissue type plasminogen activator versus intravenous streptokinase in acute myocardial infarction. Lancet, i:842–847 (1985).CrossRefGoogle Scholar
  8. 8.
    M. Verstraete, A. E. R. Arnold, R. W. Brower et al. Acute coronary thrombolysis with recombinant human tissue type plasminogen activator - initial patency and influence of a maintained infusion on reocclusion rate. Am. J. Cardiol.,60:231–7 (1987).PubMedCrossRefGoogle Scholar
  9. 9.
    M. L. Simoons, A. E. R. Arnold, A. Betriu et al. Thrombolysis with rt-PA in acute myocardial infarction: no additional benefit of immediate PTCA. Lancet, i;(1988).Google Scholar
  10. 10.
    F. van de Werf, A. E. R. Arnold, and the European Cooperative Study Group for Recombinant Tissue Plasminogen Activator. Effect of intravenous tissue plasminogen activator on infarct size, left ventricular function and survival in patients with acute myocardial infarction. Br. Med. J., (1988).Google Scholar
  11. 11.
    J.H. Chesebro, G. Knatterud, R. Roberts et al. Thrombolysis in myocardial infarction (TIMI) trial, Phase I: a comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Circulation, 76:142–54 (1987).PubMedCrossRefGoogle Scholar
  12. 12.
    E. Passamani. Thrombolysis in myocardial infarction: the NHLBI experience, in: Sobel B.E., Collen D., Grossbard EB (eds). Tissue Plasminogen Activator in Thrombolytic Therapy. M. Dekker, New York/Basel, pp75–86 (1986).Google Scholar
  13. 13.
    TIMI Study Group. Comparison of invasive and conservative strategies after treatment with intravenous tissue plasminogen activator in acute myocardial infarction: results of the thrombolysis in myocardial infarction (TIMI) phase II trial. New Engl. J. Med., 320:618–26 (1989).CrossRefGoogle Scholar
  14. 14.
    E. J. Topol, R. M. Califf, B. S. George et al. A randomized trial of immediate versus delayed elective angioplasty after intravenous tissue plasminogen activator in acute myocardial infarction. N. Engl. J. Med., 317:581–88 (1987).PubMedCrossRefGoogle Scholar
  15. 15.
    R. G. Wilcox, G. von der Lippe, C. G. Olsson, G. Jensen, A. M. Skene, J. R. Hampton. Trial of tissue plasminogen activator for mortality reduction in acute myocardial infarction: Anglo Scandinavian Study of early thrombolysis (ASSET). Lancet, ii: 525–30 (1988).CrossRefGoogle Scholar
  16. 16.
    M. O’Rourke, D. Baron, A. Keogh et al. Limitation of myocardial infarction by early infusion of recombinant tissue type plasminogen activator. Circulation,77(6):13311–5 (1988).Google Scholar
  17. 17.
    National Foundation of Australia Coronary Thrombolysis Group. Coronary thrombolysis and myocardial salvage by tissue plasminogen activator given up to 4 hours after onset of myocardial infarction. Lancet, i:203–8 (1988).Google Scholar
  18. 18.
    A. D. Guerci, G. Gerstenblith, J. A. Brinker, et al. A randomized trial of intravenous tissue plasminogen activator for acute myocardial infarction with subsequent randomization to elective coronary angioplasty. N. Engl. J. Med.,317:1613–18 (1987).PubMedCrossRefGoogle Scholar
  19. 19.
    ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both or neither among 17,187 cases of suspected myocardial infarction: ISIS-2. Lancet, ii:349–60 (1988).Google Scholar

Copyright information

© Springer Science+Business Media New York 1990

Authors and Affiliations

  • David P. de Bono
    • 1
  1. 1.Department of CardiologyUniversity of Leicester, Glenfield General HospitalLeicesterUK

Personalised recommendations